Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 3 | 3 | — | — | 5 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 3 | 3 | — | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Keratoconjunctivitis sicca | D007638 | EFO_1000906 | — | 1 | 2 | — | — | — | 2 |
Dry eye syndromes | D015352 | — | H04.12 | 1 | 2 | — | — | — | 2 |
Eye diseases | D005128 | EFO_0003966 | H44 | — | 1 | — | — | — | 1 |
Drug common name | Rivoglitazone |
INN | rivoglitazone |
Description | Rivoglitazone (INN) is a thiazolidinedione derivative undergoing research for use in the treatment of type 2 diabetes.
|
Classification | Small molecule |
Drug class | peroxisome proliferator activiating receptor (PPAR) agonists (thiazolidene derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | COc1ccc2nc(COc3ccc(CC4SC(=O)NC4=O)cc3)n(C)c2c1 |
PDB | — |
CAS-ID | 185428-18-6 |
RxCUI | — |
ChEMBL ID | CHEMBL2104753 |
ChEBI ID | — |
PubChem CID | 3055168 |
DrugBank | — |
UNII ID | 3A3N0634Q6 (ChemIDplus, GSRS) |